MedTrace Logo

Reducing Frailty for Older Cancer Survivors Using Supplements II

NCT06068543 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2026-03-06

No results posted yet for this study

Summary

This study is a two-arm placebo controlled randomized clinical trial, to assess the effect of a 12-week EGCG intervention on physical frailty compared to placebo in pre-frail older cancer survivors.

Conditions

Interventions

DRUG

Epigallocatechin-3-Gallate (EGCG)

800mg Epigallocatechin-3-Gallate (EGCG)

DRUG

Microcrystalline cellulose (MCC)

800mg microcrystalline cellulose (MCC)

DIETARY_SUPPLEMENT

Ascorbic Acid (Vitamin C)

250mg Ascorbic Acid (Vitamin C) taken one time daily for 12 weeks

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-25
Primary Completion
2030-01-01
Completion
2030-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06068543 on ClinicalTrials.gov